Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-29T16:56:34.120Z Has data issue: false hasContentIssue false
  • English
  • Français

The Global Innovation Model for Antibiotics Needs Reinvention

Published online by Cambridge University Press:  01 January 2021

Manica Balasegaram ,
Charles Clift  and
John-Arne Røttingen
Get access Rights & Permissions [Opens in a new window]

Extract

The dangers presented by antibiotic resistance (ABR) have now established themselves as a global health security issue. From an international policy perspective, three key pillars have been established: responsible access, conservation, and innovation. These pillars are intrinsically linked, meaning that any attempt to address one must take into account the implications for the other two.

An urgent need exists to address the innovation failure in ABR. In the field of anti-bacterials, the pipeline remains anemic in terms of therapeutics with novel mechanisms of action, new drug classes and strategies involving radically different, innovative approaches. The key reasons for this failure have already been well established. The slow development of new antibiotics is the result of a poor and uncertain commercial market and scientific challenges in research and development (R&D).

Type
JLME Supplement
Information
Journal of Law, Medicine & Ethics , Volume 43 , Issue S3 , Autumn 2015 , pp. 22 - 26
Copyright
Copyright © American Society of Law, Medicine and Ethics 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Butler, M. S. Blaskovich, M. A. Cooper, M. A., “Antibiotics in the Clinical Pipeline in 2013,” Journal of Antibiotics 66 (2013): 571–599.Google Scholar
Outterson, K., New Business Models for Sustainable Antibiotics (Chatham House, London: Royal Institute of International Affairs, 2014).Google Scholar
Outterson, K. Powers, J. H. Daniel, G. W. McClellan, M. B., “Repairing the Broken Market for Antibiotic Innovation,” Health Affairs 34, no. 2 (2015): 277–285.CrossRefGoogle Scholar
Report on the event, “Best Use of Medicines Legislation to Bring New Antibiotics to Patients and Combat the Resistance Problem,” European Medicines Agency, London, November 2013, available at <http://www.ema.europa.eu/docs/en_GB/document_library/Report/2013/12/WC500158230.pdf> (last visited May 14, 2015).+(last+visited+May+14,+2015).>Google Scholar
World Health Organization, Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination, Report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (2012), available at <http://www.who.int/phi/CEWG_Report_5_April_2012.pdf?ua=1> (last visited May 14, 2015).+(last+visited+May+14,+2015).>Google Scholar
Hollis, A. Maybarduk, P., “Antibiotic Resistance Is a Tragedy of the Commons That Necessitates Global Cooperation,” Journal of Law, Medicine & Ethics 43, no. 2 (2015): Available via aslme.org.CrossRefGoogle Scholar
Jaczynska, E. Outterson, K. Mestre-Farrandiz, J., Business Model Options for Antibiotics: Learning from Other Industries (Big Innovation Centre/Chatham House, London: Royal Institute of International Affairs, 2015); Chatham House Working Group, New Antibiotic Business Model (Chatham House, London: Royal Institute of International Affairs, 2015).Google Scholar
See Hollis, , supra note 6.Google Scholar
Longitude Prize, available at <https://longitudeprize.org/> (last visited May 14, 2015); Gavi, , “Pneumococcal AMC,” available at <http://www.gavi.org/funding/pneumococcal-amc/> (last visited May 14, 2015).+(last+visited+May+14,+2015);+Gavi,+,+“Pneumococcal+AMC,”+available+at++(last+visited+May+14,+2015).>Google Scholar
Follow-up of the report on the Consultative Expert Working Group on Research and Development: Financing and Coordination, available at <http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_28Add1-en.pdf> (last visited May 14, 2015).+(last+visited+May+14,+2015).>Google Scholar
Hoffmann, S. J. Outterson, K. Røttingen, J. A. Cars, O. Clift, C. Rizvi, Z. Rotberg, F. Tomson, G. Zorset, A., “An International Legal Framework to Address Antimicrobial Resistance,” Bulletin of the World Health Organization (2015): 93/2/15–152710.Google Scholar
Røttingen, J. A. Regmi, S. Eide, M. Young, A. J. Viergever, R. F. Årdal, C. Guzman, J. Edwards, D. Matlin, S. A. Terry, R. F., “Mapping Available Health R&D Data: What's There, What's Missing and What Role for a Global Observatory,” The Lancet 382, no. 9900 (2013): 1286–1307.Google Scholar
Grogan, K., “AMR Review Head O'Neill Calls for $2 Billion Innovation Fund,” Pharma Times, available at <http://www.pharmatimes.com/Article/15-02-27/AMR_review_head_O_Neill_calls_for_2_billion_innovation_fund.aspx> (last visited May 14, 2015). (last visited May 14, 2015).' href=https://scholar.google.com/scholar?q=Grogan,+K.,+“AMR+Review+Head+O'Neill+Calls+for+$2+Billion+Innovation+Fund,”+Pharma+Times,+available+at++(last+visited+May+14,+2015).>Google Scholar
Jamison, D. T. Summers, L. H. Alleyne, G. et al., “Global Health 2035: A World Converging within a Generation,” The Lancet 382, no. 9908 (2013): 1898–1955.CrossRefGoogle Scholar
President's Council of Advisors on Science & Technology, Report to the President on Combating Antibiotic-Resistant Bacteria (September 2014) at 3, available at <https://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast_carb_report_sept2014.pdf> (last visited May 14, 2015). (last visited May 14, 2015).' href=https://scholar.google.com/scholar?q=President's+Council+of+Advisors+on+Science+&+Technology,+Report+to+the+President+on+Combating+Antibiotic-Resistant+Bacteria+(September+2014)+at+3,+available+at++(last+visited+May+14,+2015).>Google Scholar
See WHO, supra note 5; Holli, , supra note 6; Jaczynska, et al., supra note 7.Google Scholar
World Health Organization, “Innovation for Antibiotics Development and Preservation,” available at <http://www.who.int/phi/implementation/consultation_imnadp/en/> (last visited May 14, 2015).+(last+visited+May+14,+2015).>Google Scholar